Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Stephen R Haynes
AddedMar 31, 2024
UpdatedMay 1, 2026
Stephen R Haynes

Stephen R Haynes

Board Member, Glengary

Stephen R Haynes's Career

Glengary
Glengary

Beachwood, OH, US

Board Member· Board
SironRX Therapeutics
SironRX Therapeutics

Cleveland, OH, US

Board Member· Board
Endosphere
Endosphere

Columbus, OH, US

Board Member· Board
Cardiox
Cardiox

Columbus, OH, US

Board Member· Board
Neuros Medical
Neuros Medical

Willoughby Hills, OH, US

Board Member· Board
OnShift
OnShift

Cleveland, OH, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Stephen R Haynes's Career

Glengary
Glengary
Investment FirmInvestment Firm112002Beachwood, OH, US
Board Member· Board

Leadership at Glengary

Thomas TyrrellThomas TyrrellBoard Member
Tom SullivanTom SullivanBoard Member
Randall MyeroffRandall MyeroffBoard Member
Robert A LauerRobert A LauerBoard Member
Albert B RatnerAlbert B RatnerBoard Member
Charles A WaldorffCharles A WaldorffBoard Member
SironRX Therapeutics
SironRX Therapeutics
Series A$3.9M62010Cleveland, OH, US
Board Member· Board

Leadership at SironRX Therapeutics

Marc PennMarc PennFounder
Clay RankinClay RankinBoard Member

Similar to SironRX Therapeutics

RegeneRx BiopharmaceuticalsRegeneRx BiopharmaceuticalsRockville, MD, USPharmaceuticals, Therapeuticsest. 1982RegeneRx BiopharmaceuticalsRockville, MD, US · est. 1982

US-based RegeneRx Biopharmaceuticals specializes in commercializing Thymosin beta 4 for rapid tissue repair and regeneration.

Public · $11.7M3
CarthroniXCarthroniXLos Angeles, CA, USPharmaceuticals, Therapeuticsest. 2015CarthroniXLos Angeles, CA, US · est. 2015

CarthroniX: A pharmaceutical company providing innovative therapy and skin regeneration solutions.

Seed · $2.3M8
Juventas TherapeuticsJuventas TherapeuticsCleveland, OH, USRegenerative Therapiesest. 2007Juventas TherapeuticsCleveland, OH, US · est. 2007

Juventas Therapeutics: A clinical-stage biotech firm innovating regenerative therapies for critical diseases.

Series B · $48.7M11
Endosphere
Endosphere
Series C$14.1M52006Columbus, OH, US
Board Member· Board

Leadership at Endosphere

Kenneth BinmoellerKenneth BinmoellerCo-Founder
James T McKinleyJames T McKinleyCo-Founder
Cardiox
Cardiox
Public$18.5M112006Columbus, OH, US
Board Member· Board

Leadership at Cardiox

Philip EggersPhilip EggersFounder
Michael BunkerMichael BunkerBoard Member

Similar to Cardiox

Cardiac InsightCardiac InsightBellevue, WA, USMedical Devices, Softwareest. 2010Cardiac InsightBellevue, WA, US · est. 2010

Cardiac Insight: Innovating ECG diagnostics with advanced wearable sensors and automated software.

Public · $32.3M44
Neuros Medical
Neuros Medical

Willoughby Hills, OH, US

Board Member· Board
OnShift
OnShift

Cleveland, OH, US

Board Member· Board

Stephen R Haynes's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Stephen R Haynes

Stephen SmithStephen SmithCo-Founder · IntellisparkDavid HaynieDavid HaynieCo-Founder · CitySparkBjörn StansvikBjörn StansvikFounder · CohereumSasha MacKinnonSasha MacKinnonCo-Founder · DatagptRyan MyersRyan MyersCEO · SparkRiseTed KrantzTed KrantzBoard Member · data.ai